Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Daniel W BowlesDivision of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO.ORCID 0000-0003-1406-0963
Robert C DoebeleDivision of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO.
Aaron S MansfieldDivision of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9483-6903
Christina S BaikDivision of Medical Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Gilberto de Lima LopesSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0002-1151-9903
Luis Paz-AresHospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Complutense University & Ciberonc, Madrid, Spain.ORCID 0000-0002-1947-3364
Matthew H TaylorEarle A. Chiles Research Institute, Providence Medical Center, Portland, OR.ORCID 0000-0003-2409-9001
Daniel S W TanDepartment of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.ORCID 0000-0002-6514-6786
Guzman AlonsoMedical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Shirish M GadgeelDivision of Hematology/Oncology, Department of Medicine, Henry Ford Health, Detroit, MI.ORCID 0000-0001-5240-3811
Gregory P KalemkerianDepartment of Medicine, Hematology-Oncology, University of Michigan, Ann Arbor, MI.ORCID 0000-0003-2404-7420
Sai-Hong Ignatius OuUniversity of California Irvine School of Medicine, Orange, CA.ORCID 0000-0002-1764-4975
Anthonie J van der WekkenDepartment of Pulmonology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.ORCID 0000-0001-7175-0026
Carlos R BecerraHoag Family Cancer Institute, Newport Beach, CA.
Makenzi EvangelistNew York Oncology Hematology, Albany, NY.
Frank GriesingerDepartment of Hematology and Oncology, Pius Hospital, University Medicine Oldenburg, Oldenburg, Germany.
Yanyan LouDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-6207-9461
Julien MazièresDepartment of Thoracic Oncology, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France.ORCID 0000-0002-5921-7613
Jason M MelearTexas Oncology-Austin Midtown, The US Oncology Network, Austin, TX.ORCID 0009-0008-7943-8908
Ashish SaxenaDivision of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Michael ThomasDepartment of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-9511-055X
Sophia WangRigel Pharmaceuticals, Inc, South San Francisco, CA.
Amber ThomassenRigel Pharmaceuticals, Inc, South San Francisco, CA.
Dae Ho LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID 0000-0002-9749-4638
Dong-Wan KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.ORCID 0000-0001-5124-7132
Justin F GainorDepartment of Medicine, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, Boston, MA.ORCID 0000-0001-8697-4081
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced · full record | OpenQuestion